Stocks making the biggest moves midday: Walmart, Deere, CrowdStrike, Moderna & more

Midday movers were broadly mixed: Walmart sank 9% despite Q2 revenue topping estimates, as same-store sales rose only 2.6% vs 3.5% expected and fiscal Q3/full-year EPS guidance missed. Deere surged almost 9% after beating with $5.10 EPS on $11B revenue (vs $4.70 and $10.73B), while Webull gained over 4% on adjusted operating income of $62.6M and revenue of $198.8M vs $33.5M and $183M expected. Crypto-linked stocks rallied on a push for crypto-friendly legislation (e.g., Coinbase/Strategy/Circle ~8%, Mara +12%), while Moderna plunged 25% after a prior 177% surge reversed on the skin-cancer vaccine trial outcome.

Analysis

The cleanest read-through is not “consumer collapse,” but margin fragility where traffic is already soft. When a scale retailer trims outlook despite beating revenue, the market should assume pricing is doing more of the work than units; that tends to compress multiples across low-end discretionary and supplier names before it shows up in the broad averages. Advance Auto and Coty reinforce that the weaker end of the consumer is not just trading down — it is forcing more promo intensity, which is negative for gross margin and for vendors that rely on shelf productivity.

By contrast, Nordson is the better-quality cyclical signal: an outlook raise in an equipment/consumables business usually means end markets are still funding capex, even if consumer indicators wobble. That sets up a relative-value split between industrials with backlog visibility and retail/consumer names where earnings revisions are turning down. Transocean’s contract is supportive for utilization, but one award does not change the equity story unless it is followed by a broader dayrate reset.

The most crowded, fragile move is crypto-related beta. These names are trading policy headlines and spot price momentum, not fundamental earnings revisions, so the upside can continue for days if the legislative narrative stays alive, but it can reverse violently on any delay or BTC rollover. Moderna’s downside looks more like de-risking around commercial uncertainty than a clean read on the asset itself; after a 1-day vertical move, the burden is now on disclosure of economics and label scope, otherwise the move is likely to mean-revert.

Contrarian view: the market may be over-reading the consumer weakness as macro when the sharper edge is stock-specific margin pressure. The better short is not simply “retail,” but names where valuation still assumes resilient traffic or cheap balance-sheet optionality. In that framework, the strongest trade is relative value, not outright beta.

Key Decisions for Investors

• Long NDSN / short WMT for 1-3 months: express a split between industrial capex resilience and consumer margin compression; target 8-12% relative outperformance if revisions keep drifting lower for retail while industrial guidance holds.
• Short WOLF on any rebound or use a put spread over the next 1-2 months: the issue is not a 50 bps revenue miss, it is financing and profitability fragility; thesis breaks only if margins inflect and refinancing risk disappears.
• Avoid chasing MRNA here; wait for a retracement or for Merck collaboration economics to be disclosed before initiating risk. If the stock reclaims the post-gap breakdown level without follow-through, that is the cleaner long-entry signal.
• Trade crypto beta tactically, not structurally: buy MSTR/CRCL only on BTC strength confirmation, otherwise fade momentum with defined-risk call spreads. The catalyst window is days to weeks; the move reverses quickly if legislative progress stalls.
• Keep CRWD on watch rather than selling the weakness immediately; a CTO departure is usually noise unless it is followed by customer churn or partner-channel disruption. Falsify any bearish read only if the next enterprise checks remain stable.